Home > Boards > US OTC > Biotechs >

Cytodyn Inc. (CYDY)

CYDY RSS Feed
Add CYDY Price Alert      Hide Sticky   Hide Intro
Moderator: Blane, JPG77, Bulldog88, justdafactss, Scooter McCabe, daemon57
Search This Board: 
Last Post: 2/25/2021 11:30:33 PM - Followers: 787 - Board type: Free - Posts Today: 168

 

 

CytoDyn Inc.https://content.equisolve.net/_3d295f93001ee78f64ac976856b2a4f1/cytodyn/db/198/1633/image_home.jpg
CYTODYN INC (OTC-QB)
1111 Main Street
Suite 660
Vancouver, WA 98660
Telephone: (360) 980-8524
Facsimile: (360) 980-8549
Web Site: http://www.cytodyn.com

CytoDyn believes in the future of precision medicine... more specificity, less side effects. Our target, the CCR5 receptor, has been implicated in multiple disease processes from HIV, GVHD, NASH, stroke recovery, multiple sclerosis, Parkinson's disease, to metastatic cancer. Leronlimab, our CCR5 antagonist, is a once a week, subcutaneous injection. One molecule with multiple opportunities. With precision comes the opportunity for improved safety, convenience, and enhanced efficacy for the patient.

 

Building a Broad Pipeline of Indications

The Next Generation of Monoclonal Antibody Therapy

CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications. 

How it Works

The target of Leronlimab (PRO 140) is the important immunologic receptor CCR5. The CCR5 receptor is a protein located on the surface of a variety of cells including white blood cells and cancer cells. On white blood cells, it serves as a receptor for chemical attractants called chemokines. The CCR5 receptor is also the coreceptor needed for HIV to infect healthy T-cells. Recent research has identified the CCR5 receptor as an important target for many disease processes including cancer metastasis and certain immunological conditions.

What Makes Leronlimab Different

Leronlimab is a unique humanized monoclonal antibody. Leronlimab prevents HIV from using the CCR5 receptor as an entry gateway for healthy cells; preclinical research has also shown that Leronlimab blocks calcium channel signaling of the CCR5 receptor when present on the cancer cell surface.  Calcium channel signaling of the CCR5 receptor is a crucial component to the spread of metastatic cancer.

Due to its selectivity and target specific mechanism of action, Leronlimab allows chemokine binding (CCL3, CCL4) at therapeutic doses and does not have agonist activity of the CCR5 receptor (it does not activate the immune function of the receptor). This target specificity separates Leronlimab from other CCR5 antagonists.  Other advantages of Leronlimab include improved safety profile, longer half-life, and less frequent dosing. 

Why CCR5 is a Favorable Target

The CCR5 receptor has been identified as a target in HIV, GVHD, NASH, cancer metastasis, transplantation medicine, multiple sclerosis, traumatic brain injury, stroke recovery, and a variety of inflammatory conditions. As we progress in evaluating Leronlimab (PRO 140) via a pathways approach, we are encouraged by the opportunity to build a broad pipeline of indications through label expansion following initial approval for multi-drug resistant HIV.

 


CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more.
Additionally, CytoDyn has established relationships with world-class HIV and Cancer experts who advise on the company's trial designs.


Drugs in Pipeline


Investment Highlights

  • Positioning in multi-billion dollar markets: HIV-1, Cancer and GvHD
    Has successfully completed HIV-1 Combo Pivotal Trial (PE achieved with p=0.0032; 81% of patients achieved suppressed viral load with HIV-1 RNA < 50 copies/mL; No SAEs).
    Underway Clinical trials: Phase 3 for HIV-1 Mono, Phase 2 for non-HIV Graft vs. Host Disease (GvHD) and Phase 1b/2 for triple negative breast cancer (TNBC).
    HIV-1 Combo BLA submissiion is expected to complete in 3Q19.

 


Leronlimab (PRO 140)

CytoDyn's lead product candidate, Leronlimab (PRO 140), belongs to a new class of HIV-1/AIDS and Cancer therapeutics intended to protect healthy cells from viral infection and supressing cancer cell metastasis. The Leronlimab (PRO 140) antibody appears to be a highly efficacious antiviral agent with minimum side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use.

Leronlimab (PRO 140) Highlights:

  • Candidate has been used in more than 800 HIV-infected patients in 8 placebo-controlled and open-label FDA-approved clinical trials;
    Was the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and
    Is designated a "fast track" product candidate by the FDA

Leronlimab (PRO 140) has also demonstrated significant advantages over standard-of-care highly active antiretroviral therapy (HAART).


How PRO-140 works 

http://www.youtube.com/watch?v=sCMwoVYeRA0&feature=youtu.be
 

 

Background

Monoclonal Antibodies

Antibodies are soluble proteins that are produced by the body in response to infections from pathogens like bacteria and viruses. Each individual antibody is synthesized by a unique cell. The secreted protein is shaped like a Y and possesses two identical yet unique binding sites that are specific for a short segment of the offending pathogen.

Vaccines capitalize on the ability of the body to produce antibodies to foreign proteins, also known as antigens, by injecting the antigen of interest with an immune stimulating molecule referred to as an adjuvant. This causes the body to react by producing antibody molecules specific for different parts of the antigen.

Once the antigen is gone from the body the antibody producing cells revert to a dormant state until the antigen is again detected in the body. Then a brisk response ensues and antibody levels rapidly rise in the bloodstream to neutralize the antigen.

Because of the genetic uniqueness among species, antibodies can also be developed that are specific for normal cell proteins. For example, immunizing a mouse with human proteins allows one to produce mouse antibodies that can recognize virtually any human antigen. This has allowed for the development of a variety of diagnostic reagents and therapeutic antibodies specific for human cells.

In the 1980s, a team of scientists won the Nobel Prize in Medicine for developing a technique that fused a common type of tumor cell with a single mouse antibody producing cell. The resulting hybrid cells all secreted the exact same antibody as the original mouse antibody producing cell and thus were called monoclonal antibodies. Since they were part tumor cell, they could be kept virtually forever in a flask. Harvesting the fluid from these cells provided an unlimited amount of highly specific monoclonal antibodies.

Monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector. The ability to transition from research reagents generated in mice to fully humanized structures suitable for clinical and commercial development has provided some of the most effective and largest selling therapeutics over the last 10 years.

 

Management

Nader Z. Pourhassan, Ph.D. Director, President and CEO

Dr. Pourhassan was appointed a Director in September 2012 and has served as CytoDyn's President and Chief Executive Officer since December 2012. Prior to that, he was the Company's Managing Director of Business Development from June 2011 to December 2012, and Chief Operating Officer from May 2008 to June 2011. Dr. Pourhassan was responsible for identifying the opportunity with leronlimab (PRO 140) and instrumental in the acquisition of this asset. He has overseen the rapid clinical development of leronlimab (PRO 140) as a therapy for HIV from Phase 2 development and into Phase 3 trials including the development of trial protocols and interaction with the U.S. Food and Drug Administration (FDA). He also has been involved in preclinical and clinical development of leronlimab (PRO 140) in additional immunological indications. Dr. Pourhassan has led CytoDyn's capital market activities since joining the Company in 2008. He has more than 20 years of business development experience. Dr. Pourhassan received his Bachelor of Science from Utah State University in 1985, his Masters of Science from Brigham Young University in 1990 and his Ph.D. in Mechanical Engineering from the University of Utah in 1998. Dr. Pourhassan has authored three books.

   

 

Michael D. Mulholland – CFO, Treasurer and Corporate Secretary

Mr. Mulholland brings to CytoDyn more than 25 years of senior level financial leadership for public companies in the business services, retail and manufacturing industries. His broad experience includes strategic planning, corporate finance, including raising debt and equity capital, acquisitions, corporate restructurings, SEC reporting, risk management, investor relations and corporate governance matters. In addition to his financial management experience, Mr. Mulholland has also managed IP-asset development for the chemical inventions of a leading European scientific inventor for improving human health, working with IP counsel to evaluate and prosecute domestic and foreign patent applications. Most recently, from 2011-2012, he served as Chief Financial Officer of Nautilus, Inc., a NYSE-listed developer and marketer of fitness equipment. He previously was Co-Chief Financial Officer of Corporate Management Advisors, Inc., a private holding company of various businesses and investments, including a majority interest in a publicly held manufacturing company, from 2010 to 2011; Vice President of Finance of Gevity HR, Inc., a former Nasdaq-listed professional employer organization, from 2008 to 2009; Chief Financial Officer and Secretary of Barrett Business Services, Inc., a Nasdaq-listed business services firm, from 1994 to 2008; and Executive Vice President, Chief Financial Officer and Secretary of Sprouse-Reitz Stores Inc., a former publicly held retail company, from 1988 to 1994. He began his career with Deloitte & Touche LLP. Mr. Mulholland received a B.S. in accounting and a M.B.A. in finance from the University of Oregon. He is a certified public accountant.

 

Nitya G. Ray, Ph.D. Chief Technology Officer - Head of Process Sciences, Manufacturing & Supply Chain

Dr. Ray rejoined CytoDyn in December 2018 and previously served as the company's Senior Vice President of Manufacturing from November 2015 to June 2017.  Most recently, Dr. Ray served as Executive Vice-President, Head of Product Development, Manufacturing and Supply Chain of Actinium Pharmaceuticals, Inc.  Prior to joining CytoDyn in 2015, Dr. Ray was Senior Vice President at Progenics Pharmaceuticals, Inc.  During his 14-year tenure at Progenics he was responsible for manufacturing, process & analytical sciences & quality control. He possesses extensive knowledge of leronlimab (PRO 140) development. Dr. Ray successfully manufactured the first 10 batches of leronlimab at Progenics under GMP, which was approved by the FDA for use in all clinical trials.

Dr. Ray’s return to CytoDyn brings 30 years of progressive, hands-on experience in strategic planning and execution of process development and manufacturing of biologics, engineered tissue therapeutics, antibody drug conjugates, and small molecule and radiopharmaceutical drugs.  He has demonstrated expertise in diverse technology platforms, product development, pre-clinical, clinical and commercial manufacturing, process and analytical sciences, quality control, global supply chain, quality systems and regulatory affairs.  Dr. Ray holds a Ph.D. in Biochemical Engineering and a M.S. degree in Chemical & Biochemical Engineering from Rutgers University and a B.S. degree in Chemical Engineering from Jadavpur University.


 

 

 

Recent Interviews

Date Link Commments
Sep 17, 2019 CytoDyn developing leronlimab (PRO140) as a pipeline in a drug BioTuesday (Featured)
Sep 9, 2019 Phase 2 FDA Clearance Proactive Interview
Aug 27, 2019 CytoDyn Inc reveals adjustment to its HIV monotherapy treatment in 'major' announcement Proactive Interview
Aug 22, 2019 cytodyn-joins-the-stock-day-podcast-to-discuss-phase-3-trials-for-their-hiv-program (Audio Interview) Nader's Interview
Aug 15, 2019 The next Super Stock (YouTube Video) Nader's Interview
     
     
     
 

Recent News/PRs

Date Link Commments
Sep 9, 2019 FDA Clearance to proceed withRegorafenib as a Combination Therapy for Metastatic Colorectal Cancer  
Aug 26, 2019 Presentation  
Aug 22, 2019 https://www.newsfilecorp.com/release/47148 Nader's Interview
     
     
     
     
     
 

 

CEO AND CFO SELLING SHARES






WHICH WAS COMPLETELY EXPLAINED ON THE JAN 6, 2021 CONFERENCE CALL!


https://www.bop.gov

https://emerginggrowth.com/cytodyn-update-reveals-q1-sales-pipeline-philippine-eua-nasdaq-uplisting-high-likelihood-of-approval/



WIFE OF CHIEF MEDICAL OFFICER'S FORM 144


 
Did The Above Get Your Attention?

Good.  That's a fine example of what we called "currated information."  What is currated information?  Well it's information designed to drive desicion making one way or another before a discussion can even being.  The above serves as an example of what is wrong with selectively presenting information.  It lowers the discourse on the board.  If you are new here please pardon the dust, we are trying to improve the quality of posting here.  There has been a lot of problems recently regarding the lack of civility and low content posting.  Think of the bad part of town where the police have to sit all day because it's an unending crime wave.  Well here it's the overworked Site Admin having to come in here and fighting a never ending wave of posting violations.  

My goal is to get us back on track, increase the civility and intellectualism in our daily discourse.  You can be long, short, happy, dubious or whatever about the drug, stock, company, and management.  But I'm going to ask you to make good faith arguments, based in reason, avoiding personal attacks and doxxing.  I promise you if you follow my guide to posting you'll never see a justifable removal of your posts again.

Step One:  Remove the personality from the argument.  A lot of good posts have to get removed because someone slides an insult right at the end.

Step Two:  If you have facts, cite them in your post.

Step Three:  Avoid casting opinions of others in your posts.  There is no need to insult someone even if it makes you feel good.

Step Four:  If the argument you are addressing can't defend itself beyond making statements of opinion or emotional appeals rest assured everyone else can see that too.

Step Five:  If someone refuses to engage in good faith arguments you can ignore them, address what they've said and move on, or roll your eyes and ignore it.  Just don't engage in petty flame wars.

Step Six:  Know the rules of the site.


As for me.  Yes I am long in the stock.  Yes I think the drug has promise.  Yes I also have been disappointed with the CEO at times.  No that disappointment does not mean I look down on the company.  Now that I am moderating I intend to step back, shepherd arguments to higher levels of discourse, and give the Site Admin a break.
I invite you to join me in this bold step forward.  I ask you to refrain from posting conspiracies, politics, personal attacks, personal information and other things that turn the debate into mud flinging.
CYDY
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CYDY News: CytoDyn in discussions with regulators after CD12 data in COVID-19 02/22/2021 07:08:24 AM
CYDY News: Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to $50-60 Million, $8.60 Valuation 02/22/2021 06:18:20 AM
CYDY News: Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million Closes 2020 with $20 million. 02/12/2021 06:26:34 AM
CYDY News: Current Report Filing (8-k) 01/29/2021 08:32:33 AM
CYDY News: WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean Vacation Market; Adds Six-Room Hotel To Portfolio Interests 01/22/2021 09:48:20 AM
PostSubject
#147825  Sticky Note Why We Are Not Seeing Potential New Investors. Scooter McCabe 02/21/21 11:05:05 AM
#147375  Sticky Note kgro, I have not seen the evidence you claim CTMedic 02/17/21 11:47:35 AM
#146614  Sticky Note Great thread on Cytodyn: kgromax 02/12/21 12:10:04 PM
#146552  Sticky Note 16 people have just been banned or restricted IH Admin [Shelly] 02/12/21 08:59:38 AM
#137986  Sticky Note ATTENTION : It has become apparent that a reminder IH Admin [Meghan] 01/03/21 08:22:35 PM
#134674  Sticky Note Everybody here get back and stay on-topic. IH Geek [Dave] 12/19/20 06:20:25 PM
#98515  Sticky Note LERONLIMAB PATIENTS HAD 63% LESS SERIOUS ADVERSE EVENTS JPG77 07/26/20 07:39:44 PM
#148822   Do we find it odd some of the mjbaker84 02/25/21 11:30:33 PM
#148821   Gonna put down pencil for a while. Seems BreezeWoodAcres 02/25/21 11:17:30 PM
#148820   yankev0u - Awesome first post and informative (and daemon57 02/25/21 11:10:09 PM
#148819   Samantha Mottet is doing great today. Should be BBalls-N-CowTown 02/25/21 11:06:10 PM
#148818   Add the OLE patients who are chosen according Blue Man 02/25/21 11:06:03 PM
#148817   2 other FDA related events at around the yankev0u 02/25/21 11:02:45 PM
#148816   How do you deal with FDA changing the BBalls-N-CowTown 02/25/21 10:59:40 PM
#148815   I'm just along for the roller coaster. Heck, Blue Man 02/25/21 10:50:06 PM
#148814   It’s hard being patient when scum raid the BreezeWoodAcres 02/25/21 10:41:10 PM
#148813   One other thought, the recommended 60 day should Blue Man 02/25/21 10:30:54 PM
#148812   And it still does not mean CD12 did Blue Man 02/25/21 10:22:44 PM
#148811   True. But, the results of CD12, if they Blue Man 02/25/21 10:20:21 PM
#148810   Don’t know if this has been answered but BreezeWoodAcres 02/25/21 10:15:41 PM
#148809   It’s a good question Blue Man. I’m not MFGinvestor 02/25/21 10:15:15 PM
#148808   Ask what should we honestly expect? Will data mjbaker84 02/25/21 10:14:45 PM
#148807   True. Better to have more buyers than supply... mjbaker84 02/25/21 10:12:04 PM
#148806   Does anyone get the sense that the FDA shadys 02/25/21 10:09:54 PM
#148805   So, would they be discussing the possibility of Blue Man 02/25/21 10:08:39 PM
#148804   MFGinvestor - This actually answered my previous questions daemon57 02/25/21 09:50:36 PM
#148803   If there are any questions for a bio 3X Charm 02/25/21 09:49:49 PM
#148802   This is what “moving the goal posts” looks like. PNW_Ironman 02/25/21 09:45:35 PM
#148801   Hear, hear. NP is an incompetent boob mercurio 02/25/21 09:36:34 PM
#148799   FDA Changes EndPoint Guidelines for Severe/Critically Ill COVID MFGinvestor 02/25/21 09:23:12 PM
#148798   That would be what I call “ a 3X Charm 02/25/21 09:12:21 PM
#148797   Give me a break. What is inaccurate? The 3X Charm 02/25/21 09:08:48 PM
#148796   But if they succeeded with hiv would there mjbaker84 02/25/21 08:41:39 PM
#148793   Not so fast. Dr. Paterson identified The CoVID 3X Charm 02/25/21 08:22:17 PM
#148791   I thought j and j approval happened yesterday? mjbaker84 02/25/21 08:16:18 PM
#148790   Tomorrow we get word that J&J vaccine will BreezeWoodAcres 02/25/21 06:38:48 PM
#148789   Great, look forward to hearing what he has Upside08 02/25/21 06:31:13 PM
#148788   That was really heavy-handed. Very bad for business BBalls-N-CowTown 02/25/21 06:26:36 PM
#148787   Look at the 1 day graph for CYDY, AngryMan 02/25/21 06:25:21 PM
#148785   Hog Killer , possibly some countries may have misiu143 02/25/21 06:13:28 PM
#148784   Misiu, I agree. Do you think these type Hog Killer 02/25/21 06:08:37 PM
#148783   Yes Tradinplaces , Most of us felt the misiu143 02/25/21 06:08:14 PM
#148782   I just hope that the "short" that made JMEG 02/25/21 06:08:02 PM
#148781   Longs - For those in the know, would daemon57 02/25/21 06:05:03 PM
#148780   Neither one of us are under an NDA 3X Charm 02/25/21 06:01:51 PM
#148779   No way I would show him that PR. 3X Charm 02/25/21 05:58:38 PM
#148778   Misu, So exciting!!! Covid is just the warm tradinplaces 02/25/21 05:58:08 PM
#148777   So the door isnt locked with nobody answering justdafactss 02/25/21 05:56:33 PM
#148776   Sorry missed the two in the bathroom!! Upside08 02/25/21 05:54:58 PM
#148775   Hog Killer , - interesting , I misiu143 02/25/21 05:53:09 PM
#148774   I counted 21 moneycrew 02/25/21 05:52:31 PM
#148773   19 people currently working FYI Upside08 02/25/21 05:43:43 PM
#148772   Why would he discuss a competitive company under Upside08 02/25/21 05:43:09 PM
#148771   Nader is working overtime to see how he KobeF 02/25/21 05:38:08 PM
#148770   Misiu, Check out our fave Big Pharma. Hog Killer 02/25/21 05:35:27 PM
#148769   Im here...looking at my 7 figure CYDY investment...looking TheBigTicket 02/25/21 05:34:20 PM
#148768   Hi Breeze, Hog Killer 02/25/21 05:31:51 PM
PostSubject
Consent Preferences